Celsion Corporation (CLSN)

[kris_kade]

Agree and I am as well.

Two big fallacies on his so called 'short thesis'

1. Trial comparison he quoted is not apples to appls. LTSL beats hands down TTSL or NTSL. The concentrated delivery and impact it makes on the tumors is undeniable.

2. The inclusion criteria requires any DR or exhepatic tumors to be NEW and not existing that's left untreated. The chances of this happening with LR tumors fully killed with no cancer cells left is minimal, IMHO.